Core Insights - BeOne Medicines Ltd. reported a revenue of $1.41 billion for the quarter ended September 2025, marking a 41% increase year-over-year and exceeding the Zacks Consensus Estimate by 5.36% [1] - The company's EPS for the quarter was $1.09, a significant improvement from -$1.15 in the same quarter last year, resulting in an EPS surprise of 51.39% compared to the consensus estimate of $0.72 [1] Revenue Breakdown - Product Revenue from TEVIMBRA was $190.62 million, slightly below the estimated $198.95 million [4] - Product Revenue from BRUKINSA (Zanubrutinib) reached $1.04 billion, surpassing the average estimate of $1.01 billion [4] - Net product revenues totaled $1.4 billion, representing a 40.4% increase compared to the previous year and exceeding the estimated $1.35 billion [4] - Product Revenue from KYPROLIS was $18.37 million, below the average estimate of $20.11 million [4] - Product Revenue from BLINCYTO was $30.48 million, exceeding the average estimate of $25.67 million [4] - Product Revenue from POBEVCY was $10.5 million, below the average estimate of $12.33 million [4] - Product Revenue from Other sources was $20.11 million, slightly above the estimated $17.76 million [4] - Product Revenue from XGEVA was $84.24 million, significantly higher than the average estimate of $66.23 million [4] Stock Performance - Over the past month, BeOne Medicines Ltd. shares have returned -8.5%, contrasting with the Zacks S&P 500 composite's +1.3% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]
BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates